The US FDA Approves Eli Lilly’s Jaypirca (Pirtobrutinib) for Certain Patients with Previously Untreated CLL/SLL

Shots: The US FDA has approved an additional indication for Jaypirca (pirtobrutinib, 100 & 50mg) for the treatment of adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion Approval was based on the P-III (BRUIN CLL-313) trial data P-III assessing Jaypirca (200mg, PO, QD until disease progression or unacceptable toxicity) vs chemoimmunotherapyin 282 treatment-naïve CLL/SLL pts without 17p deletions At mFU of 28mos., trial showed improvement in IRC-assessed PFS (1EP) with the mPFS not reached for pirtobrutinib vs 33.5mos. Plus, ORR was 94% vs 81% (CR: 13% vs 21%, PR: 81% vs 60%); data were published in The JCO Ref: Eli Lilly  |   Image: Eli Lilly   |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post The US FDA Approves Eli Lilly’s Jaypirca (Pirtobrutinib) for Certain Patients with Previously Untreated CLL/SLL appeared first on PharmaShots.